Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (October 2020)
24 slides from Cogstate's shareholder meeting presentation, Oct 27, 2020
Slide 1: Annual General Meeting
For personal use only Annual General Meeting Tuesday 27 October 2020 © 2020 Cogstate Ltd. All rights reserved.
Slide 2: Board of Directors
Board of Directors For personal use only Martyn Myer Ingrid Player Non-Executive Chairman Non-Executive Director Member: Audit, Risk & Compliance Chair: Audit, Risk & Compliance Committee Committee Chair: Remuneration & Nomination Member: Remuneration & Nomination Committee Committee David Dolby Ric
Slide 3: Founding Vision
For personal use only Founding Vision To make assessment of brain health as simple, common and informative as assessment of blood pressure 3
Slide 4: Business Segments
Business Segments For personal use only Clinical Trials Healthcare Scientific consulting, Cognitive health assessments for individuals computerized cognitive testing, and their physicians rater training & central monitoring, remote (FDA exempt class II medical device, HIPPA assessment, and eCOA comp
Slide 5: Dementia: Facts & Figures
Dementia: Facts & Figures The other pandemic killing millions For personal use only Global figures: 50M People currently living with dementia 10M New cases every year 5-8% Est. of those over 60 living with dementia Global societal cost of 1.1% dementia as a % of global GDP 5
Slide 6: Exclusive License
Exclusive License Global License to Under the exclusive licensing arrangement, Eisai will Eisai in the For personal use only globally market Cogstate technology as a digital tool for the measurement of cognition Healthcare Market Upfront Payment to Cogstate US$15m to be paid within 45 days Annual Ro
Slide 7: Video
For personal use only Video 7
Slide 8: Eisai Deal Terms
Eisai Deal Terms For personal use only License Commercials • Worldwide, 10-year license from first commercial sale, by country • US$15m upfront • Eisai can terminate after year 5 under certain • Royalty on all revenue conditions • Minimum cumulative royalty over 10 years = • All Cogstate technology
Slide 9: For personal use only
For personal use only SCREENING As a low cost, easy to use, accessible but meaningful, tool to CLINICAL TRIALS identify memory impairment in the Cogstate technology As a widely used physician tool, a community. use throughout the scientifically valid and accepted endpoint. health ecosystem TREATMENT
Slide 10: Financial Results
For personal use only Financial Results 10
Slide 11: FY20 Summary Financial Results, by Segment
FY20 Summary Financial Results, by Segment • FY20: $2m loss for the year but significant improvement in 2H20 (profit $0.8m). For personal use only • 2nd half revenue increase of $4.3m delivered improvement in profit before tax of $3.7m. • Other expenditure consistent for the last 3 financial years (
Slide 12: FY21: Sept Quarter
FY21 : Sept Quarter For personal use only $8.3m Clinical Trials sales contracts. Up 7.8% compared to Sep-19 $42.1m Contracted Future Revenue. Up $2.7m since Jun-20 $5.8m Clinical Trials revenue. Up 52% compared to Sep-19 $6.1m Total Revenue Up 22% compared to Sep-19 12
Slide 13: Financial Outlook
1 Global Healthcare License For personal use only 2 Growing Clinical Trials Business Financial Outlook 3 Cash: Enhanced by $15m Payment 4 Profitable FY21 13
Slide 14: Questions
For personal use only Questions 14
Slide 15: Formal Resolutions
For personal use only Formal Resolutions 15
Slide 16: Receipt of Financial Statements and Reports
Resolution 1 Receipt of Financial Statements and For personal use only Reports 16
Slide 17: Adoption of the Remuneration Report
Adoption of the Remuneration Report Resolution 2 (non-binding) For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: Resolution 3a That the Remuneration Report as disclosed in the Annual Directors' Report for the year ended 30 June 2020 be
Slide 18: Re-election of Martyn Myer
Re-election of Martyn Myer To consider and, if thought fit, pass the following resolution as an ordinary Resolution 2 resolution: For personal use only That Mr Martyn Myer, a Director of the Company who retires by rotation at this AGM in accordance with clause 48.1.2 of the Company’s Constitution Re
Slide 19: Re-election of Richard van den Broek
Re-election of Richard van den Broek To consider and, if thought fit, pass the following resolution as an ordinary Resolution 2 resolution: For personal use only That Mr Richard van den Broek, a Director of the Company who retires by Resolution 3a rotation at this AGM in accordance with clause 48.1.
Slide 20: Issue of options to CEO
Issue of options to CEO To consider and, if thought fit, to pass the following resolution as an Resolution 2 ordinary resolution: For personal use only That for the purpose of ASX Listing Rule 10.14 and for all other purposes, Resolution 3a the proposed issue to Mr Bradley O’Connor of 1,250,000 opti
Slide 21: Increase in Non-Executive Directors' Fee Pool
Increase in Non-Executive Directors’ Resolution 2 Fee Pool For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: Resolution 3a That, for the purposes of ASX Listing Rule 10.17 and clause 51.1 of the Constitution of the Company, and for all
Slide 22: For personal use only
G Cogstate Ajuo asn feuosied 105
Slide 23: Appendix
For personal use only Appendix 23
Slide 24: Commercial Opportunities
Direct to consumer Commercial Home based, self assessment of memory. Opportunities For personal use only “Do I need to talk to the doctor about my memory?” Annual Health Check Conducted in physicians’ office or workplace. “Am I the same as last year?” Case Finding Screening tool for general practice